up-to-date with a click!
Update - August, 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications August 2017

Other

  1. Ballard AY, Kessler M, Scheitel M et al. Exploring differences in the use of the statin choice decision aid and diabetes medication choice decision aid in primary care. BMC medical informatics and decision making 2017; 17:118. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797295
  2. Ghanem F, Vodnala D, J KK et al. Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features. Journal of biomedical research 2017; 31:82-94. http://www.ncbi.nlm.nih.gov/pubmed/?term=28808190
  3. Bensimon L, Hale G. Acclimating to the Increase in Statin Use in Accountable Care Organizations Based on Changes in Quality Measures: A Report from the Accountable Care Organization Research Network, Services, and Education. Journal of managed care & specialty pharmacy 2017; 23:943-944. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854072
  4. Wade RL, Patel JG, Hill JW et al. Estimation of Missed Statin Prescription Use in an Administrative Claims Dataset. Journal of managed care & specialty pharmacy 2017; 23:936-942. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854076
  5. Cheng J, Ukwatta E, Shavakh S et al. Sensitive three-dimensional ultrasound assessment of carotid atherosclerosis by weighted average of local vessel wall and plaque thickness change. Medical physics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28782187
  6. Abdelmaksoud AA, Girerd PH, Garcia EM et al. Association between statin use, the vaginal microbiome, and Gardnerella vaginalis vaginolysin-mediated cytotoxicity. PLoS One 2017; 12:e0183765. http://www.ncbi.nlm.nih.gov/pubmed/?term=28846702
 

Add on treatments

  1. Marazzi G, Campolongo G, Pelliccia F et al. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28781026
  2. Teramoto T, Kiyosue A, Iimura T et al. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768921
  3. Min KL, Park MS, Jung J et al. Comparison of Pharmacokinetics and Safety of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803122
  4. Yagi S, Fukuda D, Aihara KI et al. n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835582
  5. Elsaid O, Taylor B, Zaleski A et al. Rationale for investigating metformin as a protectant against statin-associated muscle symptoms. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764958
  6. El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858387
  7. Konstantinov VO. [The Role of non-Statin Therapy for Lowering the Concentration of low-Density Lipoprotein Cholesterol and Reducing the Risk of Developing Atherosclerotic Cardiovascular Complications]. Kardiologiia 2017; 57:68-72. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762924
  8. Koh KK, Sakuma I, Shimada K et al. Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events. Korean Circ J 2017; 47:432-439. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765731
  9. Zinellu A, Sotgia S, Sotgiu E et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, metabolism, and cardiovascular diseases : NMCD 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28755807
  10. Cheung DW, Koon CM, Wong PH et al. Evaluating Efficacy and Safety of Combination Medication of Atorvastatin and a Herbal Formula Containing Salvia miltiorrhiza and Pueraria lobata on Hyperlipidemia. Phytotherapy research : PTR 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840970
  11. Wat E, Ng CF, Koon CM et al. The adjuvant value of Herba Cistanches when used in combination with statin in murine models. Scientific reports 2017; 7:9391. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839280
 

Adherence

  1. Alburikan KA, Asiri RM, Alhammad AM et al. Utilization and adherence to guideline-recommended lipid-lowering therapy at an academic medical center. Annals of Saudi medicine 2017; 37:276-281. http://www.ncbi.nlm.nih.gov/pubmed/?term=28761026
  2. Ballard AY, Kessler M, Scheitel M et al. Exploring differences in the use of the statin choice decision aid and diabetes medication choice decision aid in primary care. BMC medical informatics and decision making 2017; 17:118. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797295
  3. Wawruch M, Zatko D, Wimmer G, Jr. et al. Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28791591
  4. Hyun KK, Brieger D, Woodward M et al. The effect of socioeconomic disadvantage on prescription of guideline-recommended medications for patients with acute coronary syndrome: systematic review and meta-analysis. International journal for equity in health 2017; 16:162. http://www.ncbi.nlm.nih.gov/pubmed/?term=28859658
  5. Lee M, Saver JL, Wu YL et al. Utilization of Statins Beyond the Initial Period After Stroke and 1-Year Risk of Recurrent Stroke. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768645
  6. Schroff P, Gamboa CM, Durant RW et al. Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28847913
  7. Bensimon L, Hale G. Acclimating to the Increase in Statin Use in Accountable Care Organizations Based on Changes in Quality Measures: A Report from the Accountable Care Organization Research Network, Services, and Education. Journal of managed care & specialty pharmacy 2017; 23:943-944. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854072
  8. Wade RL, Patel JG, Hill JW et al. Estimation of Missed Statin Prescription Use in an Administrative Claims Dataset. Journal of managed care & specialty pharmacy 2017; 23:936-942. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854076
  9. Steely AM, Callas PW, Hohl PK et al. Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28830706
  10. Xie G, Sun Y, Myint PK et al. Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis 2017; 16:155. http://www.ncbi.nlm.nih.gov/pubmed/?term=28810873
  11. Ye S, Kronish IM. To Persist or Not to Persist: Learning From Precision Medicine to Optimize Statin Adherence. Rev Esp Cardiol (Engl Ed) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28779966
 

Atherosclerosis & Imaging

  1. Norrington K, Androulakis E, Oikonomou E et al. Statins in Aortic Stenosis. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814237
  2. Marlatt KL, Steinberger J, Rudser KD et al. The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial. Journal of adolescent and young adult oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28853979
  3. El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858387
  4. Hong JC, Blankstein R, Shaw LJ et al. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. JACC. Cardiovascular imaging 2017; 10:938-952. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797417
  5. Cheng J, Ukwatta E, Shavakh S et al. Sensitive three-dimensional ultrasound assessment of carotid atherosclerosis by weighted average of local vessel wall and plaque thickness change. Medical physics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28782187
  6. Matsui S, Kajikawa M, Hida E et al. Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naive Individuals. Scientific reports 2017; 7:8422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28827781
  7. Cheng SF, Brown MM. Contemporary medical therapies of atherosclerotic carotid artery disease. Seminars in vascular surgery 2017; 30:8-16. http://www.ncbi.nlm.nih.gov/pubmed/?term=28818261
  8. Han Y, Yang CK, Gao CY et al. [Association between the ApoB/A1 ratio and the vulnerability of LMCA plaque in the patients with stable angina pectoris]. Zhonghua yi xue za zhi 2017; 97:2101-2106. http://www.ncbi.nlm.nih.gov/pubmed/?term=28763883
 

Atorvastatin/Rosuvastatin

  1. Wang ZS, Huang HR, Zhang LY et al. Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo. Biological & pharmaceutical bulletin 2017; 40:1247-1254. http://www.ncbi.nlm.nih.gov/pubmed/?term=28769006
  2. Chen B, Zhang M, Xing D, Feng Y. Atorvastatin enhances radiosensitivity of hypoxia-induced prostate cancer cells related with HIF-1alpha inhibition. Bioscience reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28760843
  3. El-Mohandes EM, Moustafa AM, Khalaf HA, Hassan YF. The role of mast cells and macrophages in amiodarone induced pulmonary fibrosis and the possible attenuating role of atorvastatin. Biotechnic & histochemistry : official publication of the Biological Stain Commission 2017:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836856
  4. Teramoto T, Kiyosue A, Iimura T et al. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768921
  5. Ying L, Yan F, Zhao Y et al. (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis related genes in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28815679
  6. Chen Y, Li D, Jing J et al. Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807393
  7. Min KL, Park MS, Jung J et al. Comparison of Pharmacokinetics and Safety of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803122
  8. Zhao S, Peng D. Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomised, double blind, active-controlled study. Current medical research and opinion 2017:1-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836458
  9. Rababa HA, Hijjawi TB, Alzoubi KH et al. The Nephroprotective Effect of N-Acetyl-L-Cysteine and Atorvastatin against Imipenem induced Nephrotoxicity. Current molecular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762308
  10. Lee JH, Kim SH, Choi DJ et al. Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial. Drug design, development and therapy 2017; 11:2277-2285. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814835
  11. Liu JE, Liu XY, Chen S et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812116
  12. Madbouly Taha N, Salah AYHA, El-Sayed SH et al. Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice. Experimental parasitology 2017; 181:57-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764965
  13. Sanfelice RA, Machado LF, Bosqui LR et al. Activity of rosuvastatin in tachyzoites of Toxoplasma gondii (RH strain) in HeLa cells. Experimental parasitology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28774497
  14. Liu MW, Liu R, Wu HY et al. Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression. Experimental and therapeutic medicine 2017; 14:917-930. http://www.ncbi.nlm.nih.gov/pubmed/?term=28810543
  15. Priti K, Agrawal A, Ranwa BL. High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis. Indian Heart J 2017; 69:453-457. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822510
  16. Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J et al. Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. International journal of endocrinology and metabolism 2017; 15:e43319. http://www.ncbi.nlm.nih.gov/pubmed/?term=28848611
  17. Marlatt KL, Steinberger J, Rudser KD et al. The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial. Journal of adolescent and young adult oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28853979
  18. Stein EA, Dann EJ, Wiegman A et al. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol 2017; 70:1162-1170. http://www.ncbi.nlm.nih.gov/pubmed/?term=28838366
  19. Furuyama F, Koba S, Yokota Y et al. Effects of Cardiac Rehabilitation on High-Density Lipoprotein-mediated Cholesterol Efflux Capacity and Paraoxonase-1 Activity in Patients with Acute Coronary Syndrome. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855433
  20. Hashikata T, Tojo T, Muramatsu Y et al. Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28824048
  21. Nenna A, Lusini M, Spadaccio C et al. Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting. Journal of cardiovascular medicine (Hagerstown, Md.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28787317
  22. Han F, Xiao QQ, Peng S et al. Atorvastatin ameliorates LPS-induced inflammatory response by autophagy via AKT/mTOR signaling pathway. Journal of cellular biochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28771872
  23. Naraoka M, Matsuda N, Shimamura N et al. Long-acting statin for aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2017:271678x17724682. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762878
  24. Awad K, Serban MC, Penson P et al. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. J Clin Lipidol 2017; 11:972-985.e979. http://www.ncbi.nlm.nih.gov/pubmed/?term=28826569
  25. Weiss MC, Berger JS, Gianos E et al. Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28801030
  26. Prado Y, Zambrano T, Salazar LA. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28833323
  27. Shehata M, Samir A, Dardiri M. Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. J Interv Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812321
  28. Xu X, Gao W, Cheng S et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. Journal of neuroinflammation 2017; 14:167. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835272
  29. Korybalska K, Kawka E, Breborowicz A, Witowski J. The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous coronary intervention: an in vitro study. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:397-405. http://www.ncbi.nlm.nih.gov/pubmed/?term=28820396
  30. Ma H, Liu Y, Xie H et al. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study. Medicine (Baltimore) 2017; 96:e7351. http://www.ncbi.nlm.nih.gov/pubmed/?term=28796030
  31. Ishihara N, Suzuki S, Tanaka S et al. Atorvastatin increases Fads1, Fads2 and Elovl5 gene expression via the geranylgeranyl pyrophosphate-dependent Rho kinase pathway in 3T3-L1 cells. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765914
  32. Li Y, Jiang T, Fu X et al. Atorvastatin protects cardiomyocytes against OGD/Rinduced apoptosis by inhibiting miR199a5p. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765953
  33. Jiang QF, Huang MY, Wu KY et al. Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury. Pharmacognosy magazine 2017; 13:430-438. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839368
  34. Cheung DW, Koon CM, Wong PH et al. Evaluating Efficacy and Safety of Combination Medication of Atorvastatin and a Herbal Formula Containing Salvia miltiorrhiza and Pueraria lobata on Hyperlipidemia. Phytotherapy research : PTR 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840970
  35. Yue R, Zuo C, Zeng J et al. Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway. Ren Fail 2017; 39:643-651. http://www.ncbi.nlm.nih.gov/pubmed/?term=28805489
  36. Zamani E, Mohammadbagheri M, Fallah M, Shaki F. Atorvastatin attenuates ethanol-induced hepatotoxicity via antioxidant and anti-inflammatory mechanisms. Research in pharmaceutical sciences 2017; 12:315-321. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855943
  37. Chamaria S, Johnson KW, Vengrenyuk Y et al. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. Scientific reports 2017; 7:7001. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765529
  38. Shen MH, Samsel P, Shen LL et al. Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/- Mice. Translational oncology 2017; 10:793-799. http://www.ncbi.nlm.nih.gov/pubmed/?term=28844017
  39. Nassaji M, Ghorbani R, Saboori Shkofte H. Previous Atorvastatin Treatment and Risk of Diabetic Foot Infection in Adult Patients: A Case-control Study. Wounds : a compendium of clinical research and practice 2017; 29:196-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762948
  40. Chen L, Li R, Huang X. [Role of atorvastatin in improving the inflammation-induced adipokine imbalance in mice with acute myocardial infarction]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2017; 42:790-795. http://www.ncbi.nlm.nih.gov/pubmed/?term=28845002
 

Basic science

  1. Wang ZS, Huang HR, Zhang LY et al. Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo. Biological & pharmaceutical bulletin 2017; 40:1247-1254. http://www.ncbi.nlm.nih.gov/pubmed/?term=28769006
  2. Chen B, Zhang M, Xing D, Feng Y. Atorvastatin enhances radiosensitivity of hypoxia-induced prostate cancer cells related with HIF-1alpha inhibition. Bioscience reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28760843
  3. El-Mohandes EM, Moustafa AM, Khalaf HA, Hassan YF. The role of mast cells and macrophages in amiodarone induced pulmonary fibrosis and the possible attenuating role of atorvastatin. Biotechnic & histochemistry : official publication of the Biological Stain Commission 2017:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836856
  4. Teramoto T, Kiyosue A, Iimura T et al. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768921
  5. Ying L, Yan F, Zhao Y et al. (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis related genes in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28815679
  6. Chen Y, Li D, Jing J et al. Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807393
  7. Min KL, Park MS, Jung J et al. Comparison of Pharmacokinetics and Safety of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803122
  8. Zhao S, Peng D. Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomised, double blind, active-controlled study. Current medical research and opinion 2017:1-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836458
  9. Rababa HA, Hijjawi TB, Alzoubi KH et al. The Nephroprotective Effect of N-Acetyl-L-Cysteine and Atorvastatin against Imipenem induced Nephrotoxicity. Current molecular pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762308
  10. Lee JH, Kim SH, Choi DJ et al. Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial. Drug design, development and therapy 2017; 11:2277-2285. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814835
  11. Liu JE, Liu XY, Chen S et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812116
  12. Madbouly Taha N, Salah AYHA, El-Sayed SH et al. Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice. Experimental parasitology 2017; 181:57-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764965
  13. Sanfelice RA, Machado LF, Bosqui LR et al. Activity of rosuvastatin in tachyzoites of Toxoplasma gondii (RH strain) in HeLa cells. Experimental parasitology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28774497
  14. Liu MW, Liu R, Wu HY et al. Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression. Experimental and therapeutic medicine 2017; 14:917-930. http://www.ncbi.nlm.nih.gov/pubmed/?term=28810543
  15. Priti K, Agrawal A, Ranwa BL. High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis. Indian Heart J 2017; 69:453-457. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822510
  16. Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J et al. Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. International journal of endocrinology and metabolism 2017; 15:e43319. http://www.ncbi.nlm.nih.gov/pubmed/?term=28848611
  17. Marlatt KL, Steinberger J, Rudser KD et al. The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial. Journal of adolescent and young adult oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28853979
  18. Stein EA, Dann EJ, Wiegman A et al. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol 2017; 70:1162-1170. http://www.ncbi.nlm.nih.gov/pubmed/?term=28838366
  19. Furuyama F, Koba S, Yokota Y et al. Effects of Cardiac Rehabilitation on High-Density Lipoprotein-mediated Cholesterol Efflux Capacity and Paraoxonase-1 Activity in Patients with Acute Coronary Syndrome. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855433
  20. Hashikata T, Tojo T, Muramatsu Y et al. Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28824048
  21. Nenna A, Lusini M, Spadaccio C et al. Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting. Journal of cardiovascular medicine (Hagerstown, Md.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28787317
  22. Han F, Xiao QQ, Peng S et al. Atorvastatin ameliorates LPS-induced inflammatory response by autophagy via AKT/mTOR signaling pathway. Journal of cellular biochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28771872
  23. Naraoka M, Matsuda N, Shimamura N et al. Long-acting statin for aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2017:271678x17724682. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762878
  24. Awad K, Serban MC, Penson P et al. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. J Clin Lipidol 2017; 11:972-985.e979. http://www.ncbi.nlm.nih.gov/pubmed/?term=28826569
  25. Weiss MC, Berger JS, Gianos E et al. Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28801030
  26. Prado Y, Zambrano T, Salazar LA. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28833323
  27. Shehata M, Samir A, Dardiri M. Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. J Interv Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812321
  28. Xu X, Gao W, Cheng S et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. Journal of neuroinflammation 2017; 14:167. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835272
  29. Korybalska K, Kawka E, Breborowicz A, Witowski J. The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous coronary intervention: an in vitro study. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2017; 68:397-405. http://www.ncbi.nlm.nih.gov/pubmed/?term=28820396
  30. Ma H, Liu Y, Xie H et al. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study. Medicine (Baltimore) 2017; 96:e7351. http://www.ncbi.nlm.nih.gov/pubmed/?term=28796030
  31. Ishihara N, Suzuki S, Tanaka S et al. Atorvastatin increases Fads1, Fads2 and Elovl5 gene expression via the geranylgeranyl pyrophosphate-dependent Rho kinase pathway in 3T3-L1 cells. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765914
  32. Li Y, Jiang T, Fu X et al. Atorvastatin protects cardiomyocytes against OGD/Rinduced apoptosis by inhibiting miR199a5p. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765953
  33. Jiang QF, Huang MY, Wu KY et al. Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury. Pharmacognosy magazine 2017; 13:430-438. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839368
  34. Cheung DW, Koon CM, Wong PH et al. Evaluating Efficacy and Safety of Combination Medication of Atorvastatin and a Herbal Formula Containing Salvia miltiorrhiza and Pueraria lobata on Hyperlipidemia. Phytotherapy research : PTR 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840970
  35. Yue R, Zuo C, Zeng J et al. Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway. Ren Fail 2017; 39:643-651. http://www.ncbi.nlm.nih.gov/pubmed/?term=28805489
  36. Zamani E, Mohammadbagheri M, Fallah M, Shaki F. Atorvastatin attenuates ethanol-induced hepatotoxicity via antioxidant and anti-inflammatory mechanisms. Research in pharmaceutical sciences 2017; 12:315-321. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855943
  37. Chamaria S, Johnson KW, Vengrenyuk Y et al. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. Scientific reports 2017; 7:7001. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765529
  38. Shen MH, Samsel P, Shen LL et al. Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/- Mice. Translational oncology 2017; 10:793-799. http://www.ncbi.nlm.nih.gov/pubmed/?term=28844017
  39. Nassaji M, Ghorbani R, Saboori Shkofte H. Previous Atorvastatin Treatment and Risk of Diabetic Foot Infection in Adult Patients: A Case-control Study. Wounds : a compendium of clinical research and practice 2017; 29:196-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762948
  40. Chen L, Li R, Huang X. [Role of atorvastatin in improving the inflammation-induced adipokine imbalance in mice with acute myocardial infarction]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2017; 42:790-795. http://www.ncbi.nlm.nih.gov/pubmed/?term=28845002
 

Cancer

  1. Wang ZS, Huang HR, Zhang LY et al. Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo. Biological & pharmaceutical bulletin 2017; 40:1247-1254. http://www.ncbi.nlm.nih.gov/pubmed/?term=28769006
  2. Chen B, Zhang M, Xing D, Feng Y. Atorvastatin enhances radiosensitivity of hypoxia-induced prostate cancer cells related with HIF-1alpha inhibition. Bioscience reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28760843
  3. Jung EJ, Chung KH, Kim CW. Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling. BMB reports 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803608
  4. Serrano NA, Kalman NS, Anscher MS. Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives. Cancer management and research 2017; 9:339-350. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814898
  5. Kou X, Yang Y, Jiang X et al. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation. Eur J Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28826913
  6. Di Lorenzo G, Sonpavde G, Pond G et al. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European urology focus 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753882
  7. Hamilton RJ. Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? European urology focus 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753767
  8. Murtola TJ, Peltomaa AI, Talala K et al. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. European urology focus 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753762
  9. Turrell FK, Kerr EM, Gao M et al. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity. Genes & development 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28790158
  10. Haukka J, Niskanen L, Auvinen A. Risk of cause-specific death in individuals with cancer - modifying role diabetes, statins, and metformin. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840596
  11. Marlatt KL, Steinberger J, Rudser KD et al. The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial. Journal of adolescent and young adult oncology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28853979
  12. Peng Y, He G, Tang D et al. Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma. Journal of Cancer 2017; 8:1655-1664. http://www.ncbi.nlm.nih.gov/pubmed/?term=28775785
  13. Shaitelman SF, Stauder MC, Allen P et al. Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. Journal of Cancer 2017; 8:2026-2032. http://www.ncbi.nlm.nih.gov/pubmed/?term=28819403
  14. Chen MJ, Cheng AC, Lee MF, Hsu YC. Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells. Journal of cellular physiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28833099
  15. Larsen SB, Dehlendorff C, Skriver C et al. Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017:Jco2016718981. http://www.ncbi.nlm.nih.gov/pubmed/?term=28806117
  16. von Schuckmann LA, Smith D, Hughes MCB et al. Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma. The Journal of investigative dermatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28842323
  17. Emilsson L, Garcia-Albeniz X, Logan RW et al. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. JAMA Oncol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822996
  18. Thoma C. Prostate cancer: Postdiagnosis statin use reduces mortality. Nat Rev Urol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858336
  19. Harshman LC, Werner L, Tripathi A et al. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762529
  20. Mikkelsen MK, Thomsen FB, Berg KD et al. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy. Scandinavian journal of urology 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28831860
  21. El-Refai SM, Black EP, Adams VR et al. Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study. Thrombosis research 2017; 158:49-58. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822240
  22. Shen MH, Samsel P, Shen LL et al. Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/- Mice. Translational oncology 2017; 10:793-799. http://www.ncbi.nlm.nih.gov/pubmed/?term=28844017

 

Children

  1. Gidding SS. Managing Patients With Homozygous Familial Hypercholesterolemia. J Am Coll Cardiol 2017; 70:1171-1172. http://www.ncbi.nlm.nih.gov/pubmed/?term=28838367
  2. Stein EA, Dann EJ, Wiegman A et al. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol 2017; 70:1162-1170. http://www.ncbi.nlm.nih.gov/pubmed/?term=28838366
 

Cost-effectiveness 

  1. Kullgren JT, Segel JE, Peterson TA et al. Availability and variation of publicly reported prescription drug prices. The American journal of managed care 2017; 23:444-448. http://www.ncbi.nlm.nih.gov/pubmed/?term=28817781
  2. Hong JC, Blankstein R, Shaw LJ et al. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. JACC. Cardiovascular imaging 2017; 10:938-952. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797417
  3. Cannon CP, Khan I, Klimchak AC et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768335

 

CVD

  1. Wang YB, Fu XH, Gu XS et al. Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome. American journal of cardiovascular disease 2017; 7:89-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=28804682
  2. Vavuranakis M, Kariori M, Siasos G et al. Statins in acute coronary syndromes. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814233
  3. Priti K, Agrawal A, Ranwa BL. High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis. Indian Heart J 2017; 69:453-457. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822510
  4. Hashikata T, Tojo T, Muramatsu Y et al. Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28824048
  5. Nenna A, Lusini M, Spadaccio C et al. Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting. Journal of cardiovascular medicine (Hagerstown, Md.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28787317
  6. Lyubarova R, Robinson JG, Miller M et al. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807460
  7. Wong ND, Zhao Y, Quek RGW et al. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28754224
  8. Lampropoulos K, Megalou A, Bazoukis G et al. Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI. J Interv Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28786142
  9. Shehata M, Samir A, Dardiri M. Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. J Interv Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812321
  10. Khoury Abdulla R, Kheder E, Yeow R et al. The impact of statin therapy on survival for inhospital cardiac arrest. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28824004
  11. Xie G, Sun Y, Myint PK et al. Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis 2017; 16:155. http://www.ncbi.nlm.nih.gov/pubmed/?term=28810873
  12. Won KB, Hur SH, Nam CW et al. Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction: A propensity score matching analysis from the Korea Acute Myocardial Infarction Registry. Medicine (Baltimore) 2017; 96:e7180. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858077
  13. Kim JS, Kim W, Park JY et al. Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis. PLoS One 2017; 12:e0183059. http://www.ncbi.nlm.nih.gov/pubmed/?term=28806769
  14. Sawano M, Kohsaka S, Abe T et al. Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. PLoS One 2017; 12:e0182687. http://www.ncbi.nlm.nih.gov/pubmed/?term=28817616
  15. Lin FJ, Tseng WK, Yin WH et al. Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Scientific reports 2017; 7:9179. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835613
  16. Zhen-Han L, Rui S, Dan C et al. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: A meta-analysis. Scientific reports 2017; 7:10091. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855628
  17. Mathisen SR, Abdelnoor M. Beneficial effect of statins on total mortality in AAA repair. Vascular medicine (London, England) 2017:1358863x17724221. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835175
 

Endothelium/inflammation

  1. Park J, Hwang I, Kim SJ et al. Atorvastatin prevents endothelial dysfunction in high glucose condition through Skp2-mediated degradation of FOXO1 and ICAM-1. Biochem Biophys Res Commun 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28802579
  2. El-Mohandes EM, Moustafa AM, Khalaf HA, Hassan YF. The role of mast cells and macrophages in amiodarone induced pulmonary fibrosis and the possible attenuating role of atorvastatin. Biotechnic & histochemistry : official publication of the Biological Stain Commission 2017:1-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836856
  3. Lai HY, Hsu LW, Tsai HH et al. CCAAT/enhancer-binding protein delta promotes intracellular lipid accumulation in M1 macrophages of vascular lesions. Cardiovascular research 2017; 113:1376-1388. http://www.ncbi.nlm.nih.gov/pubmed/?term=28859294
  4. Han F, Xiao QQ, Peng S et al. Atorvastatin ameliorates LPS-induced inflammatory response by autophagy via AKT/mTOR signaling pathway. Journal of cellular biochemistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28771872
  5. Hou HH, Liao YJ, Hsiao SH et al. Corrigendum: Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase. Scientific reports 2017; 7:46877. http://www.ncbi.nlm.nih.gov/pubmed/?term=28758642
 

Ethnicity

  1. Wanmasae S, Sirintronsophon W, Porntadavity S, Jeenduang N. The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28851085
  2. Tsujita M, Goto N, Futamura K et al. Triglyceride metabolism in Japanese kidney transplant recipients. Clinical and experimental nephrology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28849320
  3. Casagrande SS, Aviles-Santa L, Corsino L et al. HEMOGLOBIN A1C, BLOOD PRESSURE, AND LDL-CHOLESTEROL CONTROL AMONG HISPANIC/LATINO ADULTS WITH DIABETES: RESULTS FROM THE HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL). Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28816530
  4. Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J et al. Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. International journal of endocrinology and metabolism 2017; 15:e43319. http://www.ncbi.nlm.nih.gov/pubmed/?term=28848611
  5. El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858387
  6. Won KB, Hur SH, Nam CW et al. Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction: A propensity score matching analysis from the Korea Acute Myocardial Infarction Registry. Medicine (Baltimore) 2017; 96:e7180. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858077
  7. Zhen-Han L, Rui S, Dan C et al. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: A meta-analysis. Scientific reports 2017; 7:10091. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855628
 

FH

  1. Gidding SS. Managing Patients With Homozygous Familial Hypercholesterolemia. J Am Coll Cardiol 2017; 70:1171-1172. http://www.ncbi.nlm.nih.gov/pubmed/?term=28838367
  2. Stein EA, Dann EJ, Wiegman A et al. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol 2017; 70:1162-1170. http://www.ncbi.nlm.nih.gov/pubmed/?term=28838366
  3. Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28784313
  4. Batais MA, Almigbal TH, Bin Abdulhak AA et al. Assessment of physicians' awareness and knowledge of familial hypercholesterolemia in Saudi Arabia: Is there a gap? PLoS One 2017; 12:e0183494. http://www.ncbi.nlm.nih.gov/pubmed/?term=28817709  
 

Generics

  1. Stuart B, Hendrick F, Dougherty JS, Xu J. Does the offer of free prescriptions increase generic prescribing? The American journal of managed care 2017; 23:e193-e201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28817295
  2. Kent ST, Rosenson RS, Avery CL et al. PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites. Circ Cardiovasc Genet 2017; 10:e001632. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768753
  3. Lee JH, Kim SH, Choi DJ et al. Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial. Drug design, development and therapy 2017; 11:2277-2285. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814835

Genetics

  1. Wanmasae S, Sirintronsophon W, Porntadavity S, Jeenduang N. The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28851085
  2. Siddiqui MK, Veluchamy A, Maroteau C et al. CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circ Cardiovasc Genet 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28790154
  3. Liu JE, Liu XY, Chen S et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812116
  4. Levy A, Berinstein E. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Expert Opin Drug Metab Toxicol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28792790
  5. Roberts R. A Breakthrough in Genetics and Prevention of Coronary Artery Disease and its Relevance to Prevention in LMIC. Global heart 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28756179
  6. Prado Y, Zambrano T, Salazar LA. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28833323
  7. Elam MB, Majumdar G, Mozhui K et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One 2017; 12:e0181308. http://www.ncbi.nlm.nih.gov/pubmed/?term=28771594
  8. Chamaria S, Johnson KW, Vengrenyuk Y et al. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. Scientific reports 2017; 7:7001. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765529
 

Guidelines

  1. Alburikan KA, Asiri RM, Alhammad AM et al. Utilization and adherence to guideline-recommended lipid-lowering therapy at an academic medical center. Annals of Saudi medicine 2017; 37:276-281. http://www.ncbi.nlm.nih.gov/pubmed/?term=28761026
  2. Garg N, Muduli SK, Kapoor A et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J 2017; 69:458-463. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822511
  3. Gunasekaran P, Jeevanantham V, Sharma S et al. Implications of the 2013 ACC/AHA cholesterol guidelines on contemporary clinical practice for patients with atherosclerotic coronary and peripheral arterial disease. Indian Heart J 2017; 69:464-468. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822512
  4. Steely AM, Callas PW, Hohl PK et al. Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28830706
  5. Hong JC, Blankstein R, Shaw LJ et al. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. JACC. Cardiovascular imaging 2017; 10:938-952. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797417
  6. Cannon CP, Khan I, Klimchak AC et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768335
 

LDL- related parameters

  1. Wanmasae S, Sirintronsophon W, Porntadavity S, Jeenduang N. The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Cardiovasc Ther 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28851085
  2. Min KL, Park MS, Jung J et al. Comparison of Pharmacokinetics and Safety of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803122
  3. Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J et al. Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. International journal of endocrinology and metabolism 2017; 15:e43319. http://www.ncbi.nlm.nih.gov/pubmed/?term=28848611
  4. Whelton SP, Meeusen JW, Donato LJ et al. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method. J Clin Lipidol 2017; 11:1065-1072. http://www.ncbi.nlm.nih.gov/pubmed/?term=28826567
  5. El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858387
  6. Cannon CP, Khan I, Klimchak AC et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768335
  7. Yudin ZM, Yaacob LH, Hassan NB et al. Achievement of LDL Cholesterol Goal and Adherence to Statin by Diabetes Patients in Kelantan. The Malaysian journal of medical sciences : MJMS 2017; 24:44-50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814932
  8. Lin FJ, Tseng WK, Yin WH et al. Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Scientific reports 2017; 7:9179. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835613
  9. Matsui S, Kajikawa M, Hida E et al. Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naive Individuals. Scientific reports 2017; 7:8422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28827781
  10. Zhen-Han L, Rui S, Dan C et al. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: A meta-analysis. Scientific reports 2017; 7:10091. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855628
  11. Han Y, Yang CK, Gao CY et al. [Association between the ApoB/A1 ratio and the vulnerability of LMCA plaque in the patients with stable angina pectoris]. Zhonghua yi xue za zhi 2017; 97:2101-2106. http://www.ncbi.nlm.nih.gov/pubmed/?term=28763883

 

Meta-analyses

  1. Riaz H, Khan AR, Khan MS et al. Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28779871
  2. Karlson BW, Palmer MK, Nicholls SJ et al. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. Atherosclerosis 2017; 265:54-59. http://www.ncbi.nlm.nih.gov/pubmed/?term=28863328
  3. Zhang W, Zhang Y, Li CW et al. Effect of statins on chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28847550
  4. Kent ST, Rosenson RS, Avery CL et al. PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites. Circ Cardiovasc Genet 2017; 10:e001632. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768753
  5. Bays HE, Leiter LA, Colhoun HM et al. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28862926
  6. Zhao BC, Shen P, Liu KX. Perioperative Statins Do Not Prevent Acute Kidney Injury After Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials. Journal of cardiothoracic and vascular anesthesia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803772
  7. Awad K, Serban MC, Penson P et al. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. J Clin Lipidol 2017; 11:972-985.e979. http://www.ncbi.nlm.nih.gov/pubmed/?term=28826569
  8. Noyes AM, Thompson PD. The effects of statins on exercise and physical activity. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807461
  9. Emilsson L, Garcia-Albeniz X, Logan RW et al. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. JAMA Oncol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822996
  10. Wang Y, Xiong J, Niu M et al. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28777739
  11. Zhen-Han L, Rui S, Dan C et al. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: A meta-analysis. Scientific reports 2017; 7:10091. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855628

 

Metabolic Syndrome - Diabetes

  1. Rochlani Y, Kattoor AJ, Pothineni NV et al. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797470
  2. Hori E, Kikuchi C, Nagami C et al. Role of Glyceraldehyde-derived AGEs and Mitochondria in Superoxide Production in Femoral Artery of OLETF Rat and Effects of Pravastatin. Biological & pharmaceutical bulletin 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835584
  3. Ballard AY, Kessler M, Scheitel M et al. Exploring differences in the use of the statin choice decision aid and diabetes medication choice decision aid in primary care. BMC medical informatics and decision making 2017; 17:118. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797295
  4. Anyanwagu U, Mamza J, Donnelly R, Idris I. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovascular diabetology 2017; 16:107. http://www.ncbi.nlm.nih.gov/pubmed/?term=28830436
  5. Leiter LA, Muller-Wieland D, Baccara-Dinet MT et al. Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. Diabetic medicine : a journal of the British Diabetic Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28799203
  6. Garza L, Dols J, Gillespie M. An initiative to improve primary prevention of cardiovascular disease in adults with type II diabetes based on the ACC/AHA (2013) and ADA (2016) guidelines. Journal of the American Association of Nurse Practitioners 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28772017
  7. Lyubarova R, Robinson JG, Miller M et al. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807460
  8. Koh KK, Sakuma I, Shimada K et al. Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events. Korean Circ J 2017; 47:432-439. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765731
  9. Yudin ZM, Yaacob LH, Hassan NB et al. Achievement of LDL Cholesterol Goal and Adherence to Statin by Diabetes Patients in Kelantan. The Malaysian journal of medical sciences : MJMS 2017; 24:44-50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814932
  10. Lin FJ, Tseng WK, Yin WH et al. Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Scientific reports 2017; 7:9179. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835613
  11. Nassaji M, Ghorbani R, Saboori Shkofte H. Previous Atorvastatin Treatment and Risk of Diabetic Foot Infection in Adult Patients: A Case-control Study. Wounds : a compendium of clinical research and practice 2017; 29:196-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762948
     

New Treatments

  1. Sattar N, Toth PP, Blom DJ et al. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28844508
  2. Rane PB, Patel J, Harrison DJ et al. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28849360
  3. Kent ST, Rosenson RS, Avery CL et al. PCSK9 Loss-of-Function Variants, Low-Density Lipoprotein Cholesterol, and Risk of Coronary Heart Disease and Stroke: Data From 9 Studies of Blacks and Whites. Circ Cardiovasc Genet 2017; 10:e001632. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768753
  4. Teramoto T, Kiyosue A, Iimura T et al. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768921
  5. Dunbar RL, Movva R, Bloedon LT et al. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clinical and translational science 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28795506
  6. Leiter LA, Muller-Wieland D, Baccara-Dinet MT et al. Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. Diabetic medicine : a journal of the British Diabetic Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28799203
  7. Bays HE, Leiter LA, Colhoun HM et al. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28862926
  8. Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28804094
  9. Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28784313
  10. Konstantinov VO. [The Role of non-Statin Therapy for Lowering the Concentration of low-Density Lipoprotein Cholesterol and Reducing the Risk of Developing Atherosclerotic Cardiovascular Complications]. Kardiologiia 2017; 57:68-72. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762924
  11. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28847206
  12. Giugliano RP, Mach F, Zavitz K et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med 2017; 377:633-643. http://www.ncbi.nlm.nih.gov/pubmed/?term=28813214
  13. Fairman KA, Davis LE, Sclar DA. Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice. Therapeutics and clinical risk management 2017; 13:957-965. http://www.ncbi.nlm.nih.gov/pubmed/?term=28831261
 

PAD and statins

  1. Stavroulakis K, Borowski M, Torsello G, Bisdas T. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807382
  2. Mathisen SR, Abdelnoor M. Beneficial effect of statins on total mortality in AAA repair. Vascular medicine (London, England) 2017:1358863x17724221. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835175
 

Pleiotropic effects of statins

  1. Cancienne JM, Brockmeier SF, Rodeo SA, Werner BC. Perioperative Serum Lipid Status and Statin Use Affect the Revision Surgery Rate After Arthroscopic Rotator Cuff Repair. Am J Sports Med 2017:363546517717686. http://www.ncbi.nlm.nih.gov/pubmed/?term=28787187
  2. Lin PY, Chen CH, Wallace CG et al. Therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced fatty liver disease, fibrosis and inflammation in rabbit. American journal of translational research 2017; 9:3827-3841. http://www.ncbi.nlm.nih.gov/pubmed/?term=28861173
  3. Zhang W, Zhang Y, Li CW et al. Effect of statins on chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Chest 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28847550
  4. Ying L, Yan F, Zhao Y et al. (-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis related genes in non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28815679
  5. Sauerbruch T, Schierwagen R, Trebicka J. [Statins as a Therapy of Chronic Liver Disease?]. Deutsche medizinische Wochenschrift (1946) 2017; 142:1313-1318. http://www.ncbi.nlm.nih.gov/pubmed/?term=28850969
  6. Kim ML, Sung KR, Shin JA et al. Statins reduce TGF-beta2-modulation of the extracellular matrix in cultured astrocytes of the human optic nerve head. Experimental eye research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28789942
  7. Madbouly Taha N, Salah AYHA, El-Sayed SH et al. Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice. Experimental parasitology 2017; 181:57-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764965
  8. Sanfelice RA, Machado LF, Bosqui LR et al. Activity of rosuvastatin in tachyzoites of Toxoplasma gondii (RH strain) in HeLa cells. Experimental parasitology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28774497
  9. Liu MW, Liu R, Wu HY et al. Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression. Experimental and therapeutic medicine 2017; 14:917-930. http://www.ncbi.nlm.nih.gov/pubmed/?term=28810543
  10. Ma Z, Zhu L, Liu Y et al. Lovastatin Alleviates Endothelial-to-Mesenchymal Transition in Glomeruli via Suppression of Oxidative Stress and TGF-beta1 Signaling. Frontiers in pharmacology 2017; 8:473. http://www.ncbi.nlm.nih.gov/pubmed/?term=28769803
  11. Wright AP, Adusumalli S, Corey KE. Statin therapy in patients with cirrhosis. Frontline gastroenterology 2015; 6:255-261. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839820
  12. Proietti M, Laroche C, Nyvad O et al. Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28859841
  13. Nenna A, Lusini M, Spadaccio C et al. Preoperative atorvastatin reduces bleeding and blood products use in patients undergoing on-pump coronary artery bypass grafting. Journal of cardiovascular medicine (Hagerstown, Md.) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28787317
  14. Paricahua LI, Goncalves AFO, Pacheco S, Pacheco FJ. Sepsis Mortality in Critical Care and Prior Statin Therapy: A Retrospective Cohort Study in Central Argentina. J Clin Diagn Res 2017; 11:Oc17-oc21. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764218
  15. Bertl K, Parllaku A, Pandis N et al. The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy-A systematic review and meta-analysis. Journal of dentistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855141
  16. Carroll JA, Race B, Phillips K et al. Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice. The Journal of general virology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28758631
  17. Toso A, De Servi S, Leoncini M et al. Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. Journal of thrombosis and thrombolysis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840456
  18. Ma H, Liu Y, Xie H et al. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study. Medicine (Baltimore) 2017; 96:e7351. http://www.ncbi.nlm.nih.gov/pubmed/?term=28796030
  19. Kornelius E, Li HH, Peng CH et al. Mevastatin promotes neuronal survival against Abeta-induced neurotoxicity through AMPK activation. Metabolic brain disease 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840430
  20. Ishihara N, Suzuki S, Tanaka S et al. Atorvastatin increases Fads1, Fads2 and Elovl5 gene expression via the geranylgeranyl pyrophosphate-dependent Rho kinase pathway in 3T3-L1 cells. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765914
  21. Li Y, Jiang T, Fu X et al. Atorvastatin protects cardiomyocytes against OGD/Rinduced apoptosis by inhibiting miR199a5p. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765953
  22. Wang Y, Xiong J, Niu M et al. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28777739
  23. Michaelsson K, Lohmander LS, Turkiewicz A et al. Association between statin use and consultation or surgery for osteoarthritis of the hip or knee: a pooled analysis of four cohort studies. Osteoarthritis and cartilage 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28756279
  24. Jiang QF, Huang MY, Wu KY et al. Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury. Pharmacognosy magazine 2017; 13:430-438. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839368
  25. Abdelmaksoud AA, Girerd PH, Garcia EM et al. Association between statin use, the vaginal microbiome, and Gardnerella vaginalis vaginolysin-mediated cytotoxicity. PLoS One 2017; 12:e0183765. http://www.ncbi.nlm.nih.gov/pubmed/?term=28846702
  26. Yue R, Zuo C, Zeng J et al. Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway. Ren Fail 2017; 39:643-651. http://www.ncbi.nlm.nih.gov/pubmed/?term=28805489
  27. Zamani E, Mohammadbagheri M, Fallah M, Shaki F. Atorvastatin attenuates ethanol-induced hepatotoxicity via antioxidant and anti-inflammatory mechanisms. Research in pharmaceutical sciences 2017; 12:315-321. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855943
  28. Cheng KK, Swallow DM, Grosset KA, Grosset DG. Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease. Scottish medical journal 2017:36933017727432. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836927
  29. El-Refai SM, Black EP, Adams VR et al. Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study. Thrombosis research 2017; 158:49-58. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822240
  30. Nassaji M, Ghorbani R, Saboori Shkofte H. Previous Atorvastatin Treatment and Risk of Diabetic Foot Infection in Adult Patients: A Case-control Study. Wounds : a compendium of clinical research and practice 2017; 29:196-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762948
 

Primary Prevention

  1. Rochlani Y, Kattoor AJ, Pothineni NV et al. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28797470
 

Registry data

  1. Liao KF, Huang PT, Lin CC et al. Fluvastatin use and risk of acute pancreatitis: a population-based case-control study in Taiwan. BioMedicine 2017; 7:17. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840831
  2. Anyanwagu U, Mamza J, Donnelly R, Idris I. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovascular diabetology 2017; 16:107. http://www.ncbi.nlm.nih.gov/pubmed/?term=28830436
  3. Wawruch M, Zatko D, Wimmer G, Jr. et al. Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28791591
  4. Casagrande SS, Aviles-Santa L, Corsino L et al. Hemoglobin A1C, Blood Pressure, and LDL-Cholesterol Control Among Hispanic/Latino Adults With Diabetes: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28816530
  5. Di Lorenzo G, Sonpavde G, Pond G et al. Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European urology focus 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753882
  6. Murtola TJ, Peltomaa AI, Talala K et al. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. European urology focus 2016. http://www.ncbi.nlm.nih.gov/pubmed/?term=28753762
  7. Haukka J, Niskanen L, Auvinen A. Risk of cause-specific death in individuals with cancer - modifying role diabetes, statins, and metformin. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840596
  8. Proietti M, Laroche C, Nyvad O et al. Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28859841
  9. Garza L, Dols J, Gillespie M. An initiative to improve primary prevention of cardiovascular disease in adults with type II diabetes based on the ACC/AHA (2013) and ADA (2016) guidelines. Journal of the American Association of Nurse Practitioners 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28772017
  10. Campitelli MA, Maxwell CJ, Giannakeas V et al. The Variation of Statin Use Among Nursing Home Residents and Physicians: A Cross-Sectional Analysis. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28791683
  11. Albright KC, Howard VJ, Howard G et al. Age and Sex Disparities in Discharge Statin Prescribing in the Stroke Belt: Evidence From the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768644
  12. Schroff P, Gamboa CM, Durant RW et al. Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28847913
  13. Shaitelman SF, Stauder MC, Allen P et al. Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. Journal of Cancer 2017; 8:2026-2032. http://www.ncbi.nlm.nih.gov/pubmed/?term=28819403
  14. Paricahua LI, Goncalves AFO, Pacheco S, Pacheco FJ. Sepsis Mortality in Critical Care and Prior Statin Therapy: A Retrospective Cohort Study in Central Argentina. J Clin Diagn Res 2017; 11:Oc17-oc21. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764218
  15. Whelton SP, Meeusen JW, Donato LJ et al. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method. J Clin Lipidol 2017; 11:1065-1072. http://www.ncbi.nlm.nih.gov/pubmed/?term=28826567
  16. Wong ND, Zhao Y, Quek RGW et al. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28754224
  17. Larsen SB, Dehlendorff C, Skriver C et al. Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017:Jco2016718981. http://www.ncbi.nlm.nih.gov/pubmed/?term=28806117
  18. Khoury Abdulla R, Kheder E, Yeow R et al. The impact of statin therapy on survival for inhospital cardiac arrest. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28824004
  19. Bellows BK, Sainski-Nguyen AM, Olsen CJ et al. Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. Journal of managed care & specialty pharmacy 2017; 23:926-934. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854079
  20. Bensimon L, Hale G. Acclimating to the Increase in Statin Use in Accountable Care Organizations Based on Changes in Quality Measures: A Report from the Accountable Care Organization Research Network, Services, and Education. Journal of managed care & specialty pharmacy 2017; 23:943-944. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854072
  21. Wade RL, Patel JG, Hill JW et al. Estimation of Missed Statin Prescription Use in an Administrative Claims Dataset. Journal of managed care & specialty pharmacy 2017; 23:936-942. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854076
  22. Toso A, De Servi S, Leoncini M et al. Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. Journal of thrombosis and thrombolysis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840456
  23. Stavroulakis K, Borowski M, Torsello G, Bisdas T. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807382
  24. Steely AM, Callas PW, Hohl PK et al. Underutilization of antiplatelet and statin therapy after postoperative myocardial infarction following vascular surgery. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28830706
  25. Cannon CP, Khan I, Klimchak AC et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768335
  26. Xie G, Sun Y, Myint PK et al. Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis 2017; 16:155. http://www.ncbi.nlm.nih.gov/pubmed/?term=28810873
  27. Won KB, Hur SH, Nam CW et al. Evaluation of the impact of statin therapy on the obesity paradox in patients with acute myocardial infarction: A propensity score matching analysis from the Korea Acute Myocardial Infarction Registry. Medicine (Baltimore) 2017; 96:e7180. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858077
  28. Mosepele M, Letsatsi V, Mokgatlhe L et al. Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in Botswana. The open AIDS journal 2017; 11:45-51. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839514
  29. Michaelsson K, Lohmander LS, Turkiewicz A et al. Association between statin use and consultation or surgery for osteoarthritis of the hip or knee: a pooled analysis of four cohort studies. Osteoarthritis and cartilage 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28756279
  30. Kim JS, Kim W, Park JY et al. Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis. PLoS One 2017; 12:e0183059. http://www.ncbi.nlm.nih.gov/pubmed/?term=28806769
  31. Sawano M, Kohsaka S, Abe T et al. Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. PLoS One 2017; 12:e0182687. http://www.ncbi.nlm.nih.gov/pubmed/?term=28817616
  32. Mikkelsen MK, Thomsen FB, Berg KD et al. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy. Scandinavian journal of urology 2017:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28831860
  33. Chamaria S, Johnson KW, Vengrenyuk Y et al. Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. Scientific reports 2017; 7:7001. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765529
  34. Lin FJ, Tseng WK, Yin WH et al. Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Scientific reports 2017; 7:9179. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835613
  35. Cheng KK, Swallow DM, Grosset KA, Grosset DG. Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease. Scottish medical journal 2017:36933017727432. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836927
  36. De Rango P, Parente B, Farchioni L et al. Effect of statins on survival in patients undergoing dialysis access for end-stage renal disease. Seminars in vascular surgery 2016; 29:198-205. http://www.ncbi.nlm.nih.gov/pubmed/?term=28779787
  37. Fairman KA, Davis LE, Sclar DA. Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice. Therapeutics and clinical risk management 2017; 13:957-965. http://www.ncbi.nlm.nih.gov/pubmed/?term=28831261
  38. El-Refai SM, Black EP, Adams VR et al. Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study. Thrombosis research 2017; 158:49-58. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822240
  39. Mathisen SR, Abdelnoor M. Beneficial effect of statins on total mortality in AAA repair. Vascular medicine (London, England) 2017:1358863x17724221. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835175
 

Renal Disease

  1. Tsujita M, Goto N, Futamura K et al. Triglyceride metabolism in Japanese kidney transplant recipients. Clinical and experimental nephrology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28849320
  2. Zhao BC, Shen P, Liu KX. Perioperative Statins Do Not Prevent Acute Kidney Injury After Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials. Journal of cardiothoracic and vascular anesthesia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803772
  3. Zinellu A, Sotgia S, Sotgiu E et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, metabolism, and cardiovascular diseases : NMCD 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28755807
  4. Kim JS, Kim W, Park JY et al. Effects of statin therapy on clinical outcomes after acute myocardial infarction in patients with advanced renal dysfunction: A propensity score-matched analysis. PLoS One 2017; 12:e0183059. http://www.ncbi.nlm.nih.gov/pubmed/?term=28806769
  5. Sawano M, Kohsaka S, Abe T et al. Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry. PLoS One 2017; 12:e0182687. http://www.ncbi.nlm.nih.gov/pubmed/?term=28817616
  6. Zhen-Han L, Rui S, Dan C et al. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: A meta-analysis. Scientific reports 2017; 7:10091. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855628
  7. De Rango P, Parente B, Farchioni L et al. Effect of statins on survival in patients undergoing dialysis access for end-stage renal disease. Seminars in vascular surgery 2016; 29:198-205. http://www.ncbi.nlm.nih.gov/pubmed/?term=28779787
 

Reviews

  1. Rane PB, Patel J, Harrison DJ et al. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28849360
  2. Maggi P, Di Biagio A, Rusconi S et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC infectious diseases 2017; 17:551. http://www.ncbi.nlm.nih.gov/pubmed/?term=28793863
  3. Norrington K, Androulakis E, Oikonomou E et al. Statins in Aortic Stenosis. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814237
  4. Vavuranakis M, Kariori M, Siasos G et al. Statins in acute coronary syndromes. Current pharmaceutical design 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814233
  5. Levy A, Berinstein E. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Expert Opin Drug Metab Toxicol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28792790
  6. Wright AP, Adusumalli S, Corey KE. Statin therapy in patients with cirrhosis. Frontline gastroenterology 2015; 6:255-261. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839820
  7. Rosenson RS, Baker S, Banach M et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol 2017; 70:1290-1301. http://www.ncbi.nlm.nih.gov/pubmed/?term=28859793
  8. Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28804094
  9. Yagi S, Fukuda D, Aihara KI et al. n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835582
  10. Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28784313
  11. Elsaid O, Taylor B, Zaleski A et al. Rationale for investigating metformin as a protectant against statin-associated muscle symptoms. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764958
  12. Ramachandran R, Wierzbicki AS. Statins, Muscle Disease and Mitochondria. Journal of clinical medicine 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28757597
  13. Bertl K, Parllaku A, Pandis N et al. The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy-A systematic review and meta-analysis. Journal of dentistry 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855141
  14. Lampropoulos K, Megalou A, Bazoukis G et al. Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI. J Interv Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28786142
 

Safety and side effects

  1. Riaz H, Khan AR, Khan MS et al. Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28779871
  2. Merli GJ, Weitz HH. Annals Consult Guys - Is It Statin Myalgia? What a Pain! Annals of internal medicine 2017; 167:Cg1. http://www.ncbi.nlm.nih.gov/pubmed/?term=28806813
  3. Liao KF, Huang PT, Lin CC et al. Fluvastatin use and risk of acute pancreatitis: a population-based case-control study in Taiwan. BioMedicine 2017; 7:17. http://www.ncbi.nlm.nih.gov/pubmed/?term=28840831
  4. Mayor S. Index indicates cholesterol management strategy for statin related muscle pain. Bmj 2017; 358:j4041. http://www.ncbi.nlm.nih.gov/pubmed/?term=28851746
  5. Anyanwagu U, Mamza J, Donnelly R, Idris I. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovascular diabetology 2017; 16:107. http://www.ncbi.nlm.nih.gov/pubmed/?term=28830436
  6. Salna MP, Singer HM, Dana AN. Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis. Case reports in dermatological medicine 2017; 2017:3418204. http://www.ncbi.nlm.nih.gov/pubmed/?term=28831316
  7. Siddiqui MK, Veluchamy A, Maroteau C et al. CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circ Cardiovasc Genet 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28790154
  8. Dudzinska-Griszek J, Szuster K, Szewieczek J. Grip strength as a frailty diagnostic component in geriatric inpatients. Clin Interv Aging 2017; 12:1151-1157. http://www.ncbi.nlm.nih.gov/pubmed/?term=28794619
  9. Rosenson RS. Trial designs for statin muscle intolerance. Curr Opin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28832369
  10. Mammen AL. Which nonautoimmune myopathies are most frequently misdiagnosed as myositis? Curr Opin Rheumatol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28832350
  11. Liu JE, Liu XY, Chen S et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812116
  12. Levy A, Berinstein E. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments. Expert Opin Drug Metab Toxicol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28792790
  13. Nelson KL, Stenehjem D, Driscoll M, Gilcrease GW. Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. Frontiers in oncology 2017; 7:150. http://www.ncbi.nlm.nih.gov/pubmed/?term=28770167
  14. Camerino GM, Musumeci O, Conte E et al. Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study. Frontiers in pharmacology 2017; 8:500. http://www.ncbi.nlm.nih.gov/pubmed/?term=28798690
  15. Mancano MA. ISMP Adverse Drug Reactions: Levofloxacin-Induced Neuroexcitation and Hallucinations; Statin-Induced Muscle Rupture; Mefloquine-Induced Rhabdomyolysis; Methimazole-Induced Cholestatic Hepatitis; Decitabine-Induced Hand and Foot Syndrome. Hospital pharmacy 2017; 52:330-333. http://www.ncbi.nlm.nih.gov/pubmed/?term=28804147
  16. Meor Anuar Shuhaili MFR, Samsudin IN, Stanslas J et al. Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians. International journal of endocrinology and metabolism 2017; 15:e43319. http://www.ncbi.nlm.nih.gov/pubmed/?term=28848611
  17. Chen X, Cobbs A, George J et al. Endocytosis of Albumin Induces Matrix Metalloproteinase-9 by Activating the ERK Signaling Pathway in Renal Tubule Epithelial Cells. Int J Mol Sci 2017; 18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28805677
  18. Woolley MC, Stebbings S, Highton J. Statin-associated immune mediated necrotising myopathy: a New Zealand case series showing possible over-representation in Pacific Islanders. Internal medicine journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28782163
  19. Rosenson RS, Baker S, Banach M et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. J Am Coll Cardiol 2017; 70:1290-1301. http://www.ncbi.nlm.nih.gov/pubmed/?term=28859793
  20. Paricahua LI, Goncalves AFO, Pacheco S, Pacheco FJ. Sepsis Mortality in Critical Care and Prior Statin Therapy: A Retrospective Cohort Study in Central Argentina. J Clin Diagn Res 2017; 11:Oc17-oc21. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764218
  21. Elsaid O, Taylor B, Zaleski A et al. Rationale for investigating metformin as a protectant against statin-associated muscle symptoms. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28764958
  22. Ibarretxe D, Pelleja J, Ortiz N, Masana L. Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807458
  23. Noyes AM, Thompson PD. The effects of statins on exercise and physical activity. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807461
  24. Ramachandran R, Wierzbicki AS. Statins, Muscle Disease and Mitochondria. Journal of clinical medicine 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28757597
  25. Prado Y, Zambrano T, Salazar LA. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects. Journal of clinical pharmacy and therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28833323
  26. von Schuckmann LA, Smith D, Hughes MCB et al. Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma. The Journal of investigative dermatology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28842323
  27. Bellows BK, Sainski-Nguyen AM, Olsen CJ et al. Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms. Journal of managed care & specialty pharmacy 2017; 23:926-934. http://www.ncbi.nlm.nih.gov/pubmed/?term=28854079
  28. Caparros-Martin JA, Lareu RR, Ramsay JP et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 2017; 5:95. http://www.ncbi.nlm.nih.gov/pubmed/?term=28793934
  29. Jin R, Luo X, Luan K et al. Disorder of the mevalonate pathway inhibits calcium-induced differentiation of keratinocytes. Mol Med Rep 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28765912
  30. Jankovic J. Statin-related musculoskeletal pain in Parkinson's disease. Pain 2017; 158:1840. http://www.ncbi.nlm.nih.gov/pubmed/?term=28816887
  31. Elam MB, Majumdar G, Mozhui K et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One 2017; 12:e0181308. http://www.ncbi.nlm.nih.gov/pubmed/?term=28771594
  32. Wat E, Ng CF, Koon CM et al. The adjuvant value of Herba Cistanches when used in combination with statin in murine models. Scientific reports 2017; 7:9391. http://www.ncbi.nlm.nih.gov/pubmed/?term=28839280
 

Stroke and CNS

  1. Wawruch M, Zatko D, Wimmer G, Jr. et al. Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack. Clinical drug investigation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28791591
  2. Kim ML, Sung KR, Shin JA et al. Statins reduce TGF-beta2-modulation of the extracellular matrix in cultured astrocytes of the human optic nerve head. Experimental eye research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28789942
  3. Albright KC, Howard VJ, Howard G et al. Age and Sex Disparities in Discharge Statin Prescribing in the Stroke Belt: Evidence From the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768644
  4. Lee M, Saver JL, Wu YL et al. Utilization of Statins Beyond the Initial Period After Stroke and 1-Year Risk of Recurrent Stroke. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768645
  5. Naraoka M, Matsuda N, Shimamura N et al. Long-acting statin for aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2017:271678x17724682. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762878
  6. Xu X, Gao W, Cheng S et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. Journal of neuroinflammation 2017; 14:167. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835272
  7. Li G, Mayer CL, Morelli D et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28821686  
 

Triglycerides/HDL

  1. Tsujita M, Goto N, Futamura K et al. Triglyceride metabolism in Japanese kidney transplant recipients. Clinical and experimental nephrology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28849320
  2. Dunbar RL, Movva R, Bloedon LT et al. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clinical and translational science 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28795506
  3. Furuyama F, Koba S, Yokota Y et al. Effects of Cardiac Rehabilitation on High-Density Lipoprotein-mediated Cholesterol Efflux Capacity and Paraoxonase-1 Activity in Patients with Acute Coronary Syndrome. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855433
  4. El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28858387
  5. Lin FJ, Tseng WK, Yin WH et al. Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Scientific reports 2017; 7:9179. http://www.ncbi.nlm.nih.gov/pubmed/?term=28835613
  6. Han Y, Yang CK, Gao CY et al. [Association between the ApoB/A1 ratio and the vulnerability of LMCA plaque in the patients with stable angina pectoris]. Zhonghua yi xue za zhi 2017; 97:2101-2106. http://www.ncbi.nlm.nih.gov/pubmed/?term=28763883
 
 

Trials

  1. Marazzi G, Campolongo G, Pelliccia F et al. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28781026
  2. Sattar N, Toth PP, Blom DJ et al. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28844508
  3. Wang YB, Fu XH, Gu XS et al. Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome. American journal of cardiovascular disease 2017; 7:89-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=28804682
  4. Cancienne JM, Brockmeier SF, Rodeo SA, Werner BC. Perioperative Serum Lipid Status and Statin Use Affect the Revision Surgery Rate After Arthroscopic Rotator Cuff Repair. Am J Sports Med 2017:363546517717686. http://www.ncbi.nlm.nih.gov/pubmed/?term=28787187
  5. Teramoto T, Kiyosue A, Iimura T et al. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28768921
  6. Min KL, Park MS, Jung J et al. Comparison of Pharmacokinetics and Safety of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28803122
  7. Zhao S, Peng D. Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomised, double blind, active-controlled study. Current medical research and opinion 2017:1-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28836458
  8. Leiter LA, Muller-Wieland D, Baccara-Dinet MT et al. Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. Diabetic medicine : a journal of the British Diabetic Association 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28799203
  9. Camerino GM, Musumeci O, Conte E et al. Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study. Frontiers in pharmacology 2017; 8:500. http://www.ncbi.nlm.nih.gov/pubmed/?term=28798690
  10. Priti K, Agrawal A, Ranwa BL. High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis. Indian Heart J 2017; 69:453-457. http://www.ncbi.nlm.nih.gov/pubmed/?term=28822510
  11. Bays HE, Leiter LA, Colhoun HM et al. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28862926
  12. Hashikata T, Tojo T, Muramatsu Y et al. Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28824048
  13. Naraoka M, Matsuda N, Shimamura N et al. Long-acting statin for aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled trial. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2017:271678x17724682. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762878
  14. Lyubarova R, Robinson JG, Miller M et al. Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28807460
  15. Shehata M, Samir A, Dardiri M. Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. J Interv Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28812321
  16. Yudin ZM, Yaacob LH, Hassan NB et al. Achievement of LDL Cholesterol Goal and Adherence to Statin by Diabetes Patients in Kelantan. The Malaysian journal of medical sciences : MJMS 2017; 24:44-50. http://www.ncbi.nlm.nih.gov/pubmed/?term=28814932
  17. Ma H, Liu Y, Xie H et al. The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational study. Medicine (Baltimore) 2017; 96:e7351. http://www.ncbi.nlm.nih.gov/pubmed/?term=28796030
  18. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28847206
  19. Li G, Mayer CL, Morelli D et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults. Neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28821686
  20. Zinellu A, Sotgia S, Sotgiu E et al. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients. Nutrition, metabolism, and cardiovascular diseases : NMCD 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28755807
  21. Harshman LC, Werner L, Tripathi A et al. The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28762529
  22. Matsui S, Kajikawa M, Hida E et al. Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naive Individuals. Scientific reports 2017; 7:8422. http://www.ncbi.nlm.nih.gov/pubmed/?term=28827781
  23. Zhen-Han L, Rui S, Dan C et al. Perioperative statin administration with decreased risk of postoperative atrial fibrillation, but not acute kidney injury or myocardial infarction: A meta-analysis. Scientific reports 2017; 7:10091. http://www.ncbi.nlm.nih.gov/pubmed/?term=28855628
  24. Han Y, Yang CK, Gao CY et al. [Association between the ApoB/A1 ratio and the vulnerability of LMCA plaque in the patients with stable angina pectoris]. Zhonghua yi xue za zhi 2017; 97:2101-2106. http://www.ncbi.nlm.nih.gov/pubmed/?term=28763883
 

Women and elderly

  1. Campitelli MA, Maxwell CJ, Giannakeas V et al. The Variation of Statin Use Among Nursing Home Residents and Physicians: A Cross-Sectional Analysis. J Am Geriatr Soc 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28791683

 
 

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.